03/10/2024

Serum Looks Beyond COVID with New Vaccines for Malaria, Dengue

It has repurposed facilities once used to make COVID-19 immunizations

The CEO of the world's biggest vaccine maker, Serum Institute of India, said the company has bolstered its manufacturing ahead of launches over the next few years of shots against diseases like malaria and dengue by repurposing facilities used to make COVID-19 immunizations.

With COVID manufacturing scaled back as demand ebbs, the company is using those facilities to instead manufacture its newer shots, which it estimates will boost total production by two and a half billion doses, CEO Adar Poonawalla said in an interview.

Serum produces AstraZeneca's COVID-19 vaccine under the brand name Covishield in India, and it also makes Novavax's protein-based COVID shots.

Please select this link to read the complete article from Reuters.